How does an entity determine whether an intangible asset has a finite or indefinite useful life, and what are the accounting consequences of each classification?

Question

AcadiFi · Accepted Answer

Under IAS 38 and IFRS 3, every intangible asset recognized in a business combination must be classified as having either a **finite** or **indefinite** useful life. This classification drives all subsequent measurement. Here is the framework.

**Determining Useful Life — Key Factors**

The entity considers:

1. **Legal or contractual** — Is there a finite term (e.g., a patent with 12 years remaining, a broadcast license renewable every 5 years)?
2. **Expected usage patterns** — How long will the asset generate cash flows?
3. **Typical product life cycles** in the industry.
4. **Technological obsolescence** — How quickly does the technology evolve?
5. **Competitive and market factors** — Stability of demand.
6. **Maintenance expenditure** required to sustain the asset's service potential.

If **no foreseeable limit** exists on the period over which the asset will generate net cash inflows, it is classified as indefinite. This does NOT mean infinite — it means the end cannot be reliably predicted.

**Accounting Consequences**

| Feature | Finite Life | Indefinite Life |
|---|---|---|
| Amortization | Yes — systematic over useful life | No amortization |
| Impairment test | When indicators exist (IAS 36 trigger-based) | **Annually** + when indicators exist |
| Reassessment | Useful life reviewed each period | Reassess indefinite classification each period |
| Income statement impact | Amortization expense reduces earnings | No regular charge, but impairment hits P&L |

**Worked Example — Thornbridge Pharma Acquires Elara Biotech:**

Thornbridge recognizes two intangibles from the deal:

| Intangible | Classification | Rationale | Treatment |
|---|---|---|---|
| Patented drug compound "Velcara" | Finite — 9 years | Patent expires 2035, no generic competition until then | Amortize $72M over 9 years = $8M/yr |
| Trade name "Elara" | Indefinite | 30+ year brand history, ongoing R&D pipeline, no foreseeable end | No amortization; annual impairment test |

After Year 3, a competitor launches a biosimilar. Thornbridge reassesses:

- Velcara's useful life is shortened from 9 to 5 remaining years. The carrying value of $48M ($72M − $24M accumulated) is now amortized over 5 years = $9.6M/yr.
- The Elara trade name remains indefinite, but the annual impairment test reveals recoverable amount has dropped below carrying value — an impairment loss is recognized.

**Exam Pitfalls:**

1. "Indefinite" is NOT "infinite" — this distinction is a classic multiple-choice trap.
2. Reassessment is required **every period** for both classifications.
3. Changing from indefinite to finite is a **change in estimate** (prospective treatment, not restatement).

Explore the full IAS 38 framework in our CFA Level II course.

How does an entity determine whether an intangible asset has a finite or indefinite useful life, and what are the accounting consequences of each classification?

Master Level II with our CFA Course

Related Questions

Practice Questions